1. Introduction {#sec1}
===============

Hypertension is highly prevalent globally. The estimated number of people with uncontrolled hypertension is nearly 1 billion (around 15% of the world population), with the number predicted to increase to 1.56 billion by the year 2025 \[[@B1]\]. Due to its high prevalence, hypertension is the leading risk factor for cardiovascular disease, stroke, and end-stage kidney diseases. The increased risk of cardiovascular mortality and morbidity has led to the estimation that hypertension causes 13% of all deaths (around 7.5 million deaths worldwide) \[[@B2]\]. Patients are considered to have hypertension when their systolic blood pressure is ≥140 mmHg and/or their diastolic blood pressure is ≥90 mmHg \[[@B3]\]. However, raised blood pressure, even within the normal range, is positively and continuously related to mortality and morbidity---each increment of 20 (systolic)/10 (diastolic) mmHg of blood pressure doubles the risk of cardiovascular diseases \[[@B2]\]. Hence, the number of people at risk is higher as the prevalence of raised blood pressure for adults (aged ≥25 years) is around 40% \[[@B2]\].

The majority of hypertension in the general population occur idiopathically with no apparent causes and therefore are categorized as primary hypertension. The remaining hypertensive cases (about 5%) are categorized as secondary hypertension as the raised blood pressure occur secondary to other causes/diseases, for example, hypertension due to aldosteronism, pheochromocytoma, renovascular diseases, or even Mendelian forms of hypertension \[[@B4], [@B5]\]. However, despite being classified as having no apparent cause, studies of familial aggregation on primary hypertensive patients have found associations of blood pressure among siblings and between parents and children, indicating that genetic factors contribute to the high blood pressure among primary hypertensive patients. Genetic factors have been estimated to explain 30--50% of the interindividual variation in blood pressure which significantly predisposes family (siblings/children) of primary hypertensive patients to hypertension \[[@B6]\]. These heritable genetic factors, in addition to environment and demographic factors, play a major role in interindividual variation in blood pressure \[[@B7]\]. Therefore, extensive genetic research has been conducted over the years, including genome-wide association studies (GWASs), to help elucidate primary hypertension\'s heritability.

2. Outcomes of Genome-Wide Association Studies on Primary Hypertension {#sec2}
======================================================================

GWASs have identified over three hundred plus SNPs/loci associated with blood pressure and/or primary hypertension over the past decade ([Table 1](#tab1){ref-type="table"}). Meta-analyses of GWASs have made the biggest contribution as they allowed for larger sample sizes and more extensive imputation panels. Despite these advancements, genetic variation identified so far only explains \~3--6% of the variance for blood pressure, approximately 1 mmHg per allele systolic blood pressure or 0.5 mmHg per allele diastolic blood pressure \[[@B8]--[@B12]\]. Further, the vast majority of GWASs were performed predominantly in Caucasian populations with only a few studies assessing or replicating in other populations even though high blood pressure burden risk is ranked number one in Southeast Asia, Central Asia, North Africa, and Middle East \[[@B13]--[@B40]\]. This suggests the existence of many more undiscovered SNPs/loci or at the very least SNPs unique to other populations that are not of Caucasian ancestry. For example, one meta-analysis on Oriental populations found five Oriental-specific loci near *CAPZA1*, *FIGN*, *ENPEP*, *NPR3*, and *PTPN11* (near *C12orf51*) associated with hypertension \[[@B22]\]. Either the differences in environmental exposures/lifestyle factors or genetic background can explain why ethnic/racial susceptibility loci exist. Nevertheless, as even a small increase in blood pressure can increase the risk of cardiovascular diseases, the biological pathways identified by these SNPs would still be useful in resolving many of the open questions regarding blood pressure pathophysiology.

3. Biological Pathways Involved with Blood Pressure Pathophysiology {#sec3}
===================================================================

Mendelian forms of hypertension and germline mutations causing early-onset hypertension have highlighted biological pathways that involve renal salt handling (*WNK1*, *WNK4*, *KLHL3*, and *CUL3*), ion transport (*CACNA1D*, *CACNA1H*, *KCNJ5*, *SCNN1B*, and *SCNN1G*), corticosteroidogenesis (*CYP11B2*, *HSD11B2*, *NR3C2*, *CYP11B1*, and *CYP17A1*), and vascular tone (*PDE3A*) to regulate blood \[[@B41]--[@B44]\]. Thus, not surprisingly, GWASs have identified SNPs in or near to genes involved with these biological pathways associated with primary hypertension. In fact, one of the first few high-throughput genotyping was performed on only genes underlying monogenic hypertension and hypotension (not genome-wide) which found two renal sodium regulatory genes (*KCNJ1* and *NR3C2*) to have SNPs associated with blood pressure in the general population \[[@B45]\].

3.1. Renal Salt Handling {#sec3.1}
------------------------

One interesting SNP putatively involving renal salt-handling pathway was only linked to hypertension in an extreme case-control GWAS design \[[@B25]\]. This SNP, rs13333226, on chromosome 16 is in the 5′ region of *UMOD* (combined *P* value of 3.6 × 10^−11^). The minor G allele of this SNP had an OR of 0.87 (95% CI: 0.84--0.91) for hypertension, with the subject having the minor G allele having decreased urinary uromodulin and better renal function. The exclusive expression of uromodulin, the protein encoded by *UMOD*, in the thick portion of the ascending limb of Henle suggests that the SNP exerts its effect through sodium homeostasis \[[@B25]\]. Also based on renal expression, SNPs in or near to *PAPPA2* and *ADAMTS7* (rs61823001 and rs62011052, resp., \[[@B8]\]) are expected to play a role in the renal salt-handling pathway. Interestingly in regard to the protein encoded by *ADAMTS7*, angiotensin II stimulation induced renal expression of the protein \[[@B46]\]. Similarly, renal cortex expression of *PAPPA2* in Dahl salt-sensitive rats responded to changes of salt diet supporting a role of the SNP in the renal salt-handing pathway \[[@B47]\]. SNPs in *FAM186B* and *ARHGAP24* on the other hand are postulated to play a role in renal function based on involvement with kidney diseases. Combining whole exome sequencing and homozygosity mapping in consanguineous families, *FAM186B* was identified as a novel candidate gene for monogenic, recessive nephronophthisis-related ciliopathies \[[@B48]\]. *ARHGAP24* on the other hand is thought to play a role in renal cell carcinoma and focal segmental glomerulosclerosis most likely through RhoA and Rac1 signaling pathways \[[@B49], [@B50]\].

3.2. Ion Transport {#sec3.2}
------------------

Several SNPs in genes involved with ion transport have been associated with blood pressure (e.g., *ATP2B1*, *CACNA1D*, *CACNA2D2*, *CACNB2*, *KCNK3*, *SLC4A7*, and *SLC39A8*; [Table 1](#tab1){ref-type="table"}). Of these, the one most studied and replicated are SNPs in *ATP2B1* \[[@B9], [@B18], [@B22], [@B51]\]. Confirming the role of *ATP2B1* in blood pressure regulation is the vascular smooth muscle cell-specific knockout of *ATP2B1* mice which had higher systolic blood pressure and significantly increased phenylephrine-induced vasoconstrictions \[[@B52]\]. Similarly, silencing of *ATP2B1* through injection of an SiRNA complex into mouse tail veins led to an increase in blood pressure and an increase in contractile response to phenylephrine \[[@B53]\]. These results support that *ATP2B1* genetic variants are the causative gene for the association with blood pressure seen in GWASs. The other gene encoding an ion channel with significant supporting evidence is *CACNA1D*. This is because gain of function mutations in *CACNA1D* have been found to be causal for primary aldosteronism and for aldosterone-producing cell clusters \[[@B42], [@B54], [@B55]\]. As aldosterone is a key regulator of blood pressure, even small changes which may not pass the clinical threshold for primary aldosteronism may be causal for increase in blood pressure. Elevation of aldosterone may also be the mechanism of action for the other ion channels associated with primary hypertension as mutations in the ATPase Na^+^/K^+^ transporting subunit alpha 1 and G protein-activated inward rectifier K^+^ channel 4 have also been found causal for primary aldosteronism and aldosterone-producing cell clusters \[[@B55], [@B56]\].

3.3. Corticosteroidogenesis {#sec3.3}
---------------------------

Surprisingly in the sense that corticosteroids can highly affect blood pressure, only 2 cytochrome P450 enzyme genes involved with corticosteroidogenesis have been linked to hypertension by GWASs---*CYP17A1* and *CYP21A2*. And of that, only SNPs in the *CYP17A1* gene have been replicated, though even then with inconsistent results. *CYP17A1* encodes 17*α*-hydroxylase which is essential to the synthesis of cortisol precursors. Therefore, alteration of this gene can cause a deficiency in 17*α*-hydroxylase and thus cortisol, which affects blood pressure \[[@B57]\]. Supporting the role of *CYP17A1* in blood pressure regulation is the SNP rs11191548, a SNP near the *CYP17A1* gene that has been consistently associated with blood pressure in both East Asian cohorts and Caucasian cohorts \[[@B10], [@B17], [@B18], [@B58]--[@B60]\]. Patients harboring the risky C allele had lower PRA and K+ levels similar to patients with 17*α*-hydroxylase deficiency, suggesting that the SNP (which is actually in the noncoding region of the gene *CNNM2*) has an effect on the enzymatic activity of *CYP17A1* \[[@B58]\]. One hypothesis as to why inconsistent results occur with GWAS is if the association found between the lead SNP is indirect whereby the signal produced is actually caused by a synthetically linked rarer variant in linkage disequilibrium with the identified tag SNP. This could be the case with the lead SNP rs1004467 which was identified from the CHARGE + Global BPgen meta-analysis \[[@B9]\]. In an Oriental cohort (from Korea), rs1004467 was found to have a modest association with hypertension in prediabetic subjects and a significant association with augmentation index in diabetic subjects \[[@B61]\]. However, in another Oriental cohort with similar ethnic background (from China), rs1004467 association with hypertension/blood pressure was not found in children \[[@B62]\]. As such, perhaps the causal SNP is not rs1004467 as identified by the initial GWAS meta-analysis but a tag SNP with poor penetrance. Interestingly, rs1004467 is in linkage disequilibrium with rs138009835, a functional SNP located 1800 bases upstream of the transcription site of *CYP17A1*. In vitro gene reporter gene assays and clinical functional experiments found the minor alleles to have reduced mRNA expression of *CYP17A1* and reduced aldosterone excretion \[[@B63]\]. To note, both rs1004467 and rs11191548 are associated with a reduction in both visceral and subcutaneous fat mass in Japanese women \[[@B64]\].

3.4. Vascular Tone {#sec3.4}
------------------

Interestingly, although only one of the fifteen monogenic hypertension genes is postulated to mediate an effect through the vasculature, SNPs associated with blood pressure and primary hypertension are enriched in genes that are expressing their proteins in vascular smooth muscle and endothelial cells \[[@B11], [@B12], [@B65]--[@B67]\]. This is consistent with vascular tone playing a primary role in blood pressure regulation. Many of these genes, however, may have been reported as the causal genes due to their proximity to the SNP in question and their likelihood of playing a role in blood pressure regulation rather than due to real functional data \[[@B68]\]. For example, the reported gene for rs7129220, a SNP downstream to the *ADM* gene in the noncoding RNA *CAND1.11* gene, was the *ADM* gene as adrenomedullin the protein encoded by *ADM* plays a role in vasodilation \[[@B69]\]. Oppositely, the reported genes for rs633185 are *FLJ32810*-*TMEM133*, even though the SNP is within the intron of *ARHGAP42* ([Table 1](#tab1){ref-type="table"}). As a candidate gene for blood pressure regulation, *ARHGAP42* has many functional evidence to be the causal gene as reduced expression of *ARHGAP42* in mice elevated blood pressure \[[@B70]\]. To note, rs633185 is in high linkage disequilibrium with rs604723, another SNP in the intron of *ARHGAP42*, and the minor T allele is a functional variant that increases *ARHGAP42* expression by promoting serum response factor binding to a smooth muscle-selective regulatory element \[[@B71]\]. Based on this strong functional data, rs604723 is most likely the causative SNP at this locus. rs6271 in exon 11 of the *DBH* gene on the other hand is one of the rare times where GWASs had managed to directly identify a missense variant which is probably damaging to the protein dopamine *β*-hydroxylase according to PolyPhen-2 prediction \[[@B72]\]. Concurringly, severe orthostatic syndrome (postural hypotension) were found to be caused by truncating, splice site, or missense mutations in the *DBH* gene \[[@B73]\].

4. Conclusion {#sec4}
=============

Although some of the SNPs identified by GWAS on primary hypertension associates with similar biological pathways as Mendelian or early-onset forms of hypertension (validating the study approach), none of the SNPs identified had a large size effect (≤1 mmHg) to be of significance to an individual patient. The ultimate goals of performing these GWASs are to determine the genetic factors regulating blood pressure that can be used to make predictions about who is at risk of developing hypertension and to identify the biological pathways of the disease allowing for identification of novel targets for treatment or even prevention strategies. As currently no direct clinical application of these GWAS findings can be made, it is still debatable whether GWAS is the best approach to identify the biological underpinnings of primary hypertension. Even though yet-to-be-discovered Oriental-specific loci or rare SNPs that might have larger effect size may increase the variance for blood pressure that can be explained by genetic variation, information on epigenetic modulation (e.g., DNA methylation, posttranslational modifications of proteins, or even gut microbiota \[[@B20], [@B74]--[@B78]\]) may still be needed to explain the total heritability of raised blood pressure which cannot be captured by GWASs.
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Loci associated with blood pressure and/or hypertension that have been identified through large-scale studies in the past decade.

  Locus name                    SNP           Chr ID   Chr position   Coded allele   Best trait   Effect size of best trait (OR beta)   Coded allele frequency   Reporting article
  ----------------------------- ------------- -------- -------------- -------------- ------------ ------------------------------------- ------------------------ -------------------------------------------------------------------------
  *2q36.3*                      rs2972146     2        226,235,982    T              DBP          0.17                                  0.19                     Surendran et al. \[[@B29]\]
  *7q32.1*                      rs4728142     7        128,933,913    A              SBP          −0.224                                0.29                     Surendran et al. \[[@B29]\]
  *ABHD17C*                     rs35199222    15       80,720,696     A              SBP          0.322                                 0.18                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *ABHD17C*                     rs11634851    15       80,736,624     G              SBP          0.316                                 0.461                    Wain et al. \[[@B27]\]
  *ABLIM3-SH3TC2*               rs9687065     5        149,011,577    A              DBP          0.26                                  0.16                     Kato et al. \[[@B20]\]
  *ACE*                         rs4308        17       63,482,264     A              DBP          0.213                                 0.24                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *ACOX1*                       rs2467099     17       75,952,964     T              SBP          −0.307                                0.18                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *ADAMTS7-MORF4L1*             rs62012628    15       78,777,658     T              DBP          −0.238                                0.34                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *ADAMTS7-MORF4L1*             rs62011052    15       79,156,983     C              PP           −0.28                                 0.14                     Hoffmann et al. \[[@B8]\]
  *ADAMTS8*                     rs11222084    11       130,403,335    T              PP           0.337                                 0.21                     Wain et al. \[[@B19]\]
  *ADAMTS9*                     rs918466      3        64,724,577     A              DBP          −0.204                                0.35                     Ehret et al. \[[@B12]\]
  *ADCY3*                       rs55701159    2        24,916,727     T              DBP          0.285                                 0.1                      Warren et al. \[[@B26]\]
  *ADM*                         rs360157      11       9,732,674      T              SBP          0.413                                 0.44                     Ehret et al. \[[@B12]\]
  *ADM*                         rs7129220     11       10,350,538     A              SBP          −0.619                                0.058                    Ehret et al. \[[@B18]\]
  *ADM*                         rs7129220     11       10,350,538     A              DBP          −0.299                                0.058                    Ehret et al. \[[@B18]\]
  *ADO*                         rs10995311    10       62,805,174     G              DPB          −0.20                                 0.38                     Liu et al. \[[@B23]\], Surendran et al. \[[@B29]\]
  *ADRB1*                       rs2782980     10       114,021,768    T              PP           −0.338                                0.28                     Wain et al. \[[@B19]\]
  *ADRB1-RNU6-709P*             rs10787517    10       114,055,047    A              SBP          0.442                                 0.616                    Wain et al. \[[@B27]\]
  *AGT*                         rs2004776     1        230,712,956    T              SBP          0.42                                  0.41                     Johnson et al. \[[@B30]\]
  *AKT2*                        rs9710247     19       40,254,542     G              DBP          0.252                                 0.44                     Wain et al. \[[@B27]\]
  *AMH-SF3A2*                   rs740406      19       2,232,222      A              PP           −0.55                                 0.21                     Kato et al. \[[@B20]\]
  *ARHGAP12*                    rs10826995    10       31,793,730     T              PP           −0.212                                0.3                      Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *ARHGAP24*                    rs2014912     4        85,794,517     T              SBP          0.62                                  0.19                     Kato et al. \[[@B20]\]
  *ARNTL*                       rs900145      11       13,272,358     G              DBP          −0.25                                 0.43                     Liu et al. \[[@B23]\]
  *ARVCF*                       rs12628032    22       19,980,457     T              PP           0.24                                  0.27                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *ARVCF*                       rs4819852     22       20,000,644     A              PP           0.261                                 0.29                     Wain et al. \[[@B27]\]
  *ATP2B1*                      rs2681472     12       89,615,182     A              DBP          0.5                                   0.83                     Levy et al. \[[@B9]\]
  *ATP2B1*                      rs2681492     12       89,619,312     T              SBP          1.26                                  0.21                     Levy et al. \[[@B9]\]
  *ATP2B1*                      rs17249754    12       89,666,809     A              BP           0.8                                   0.35                     Kelly et al. \[[@B31]\]
  *BAT2-BAT5*                   rs805303      6        31,648,589     G              SBP          0.376                                 0.44                     Johnson et al. \[[@B30]\]
  *BDNF*                        rs11030119    11       27,706,555     A              DBP          −0.163                                0.26                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *BLK-GATA4*                   rs2898290     8        11,576,400     C              SBP          NA                                    0.38                     Ho et al. \[[@B33]\]
  *C10orf107*                   rs4590817     10       61,707,795     C              DBP          0.436                                 0.16                     Wain et al. \[[@B27]\]
  *C10orf107*                   rs1530440     10       61,764,833     T              DBP          0.19                                  0.15                     Newton-Cheh et al. \[[@B10]\]
  *C10orf32, C10orf32-ASMT*     rs4409766     10       102,856,906    T              SBP          1.24                                  0.71                     Lu et al. \[[@B51]\]
  *C17orf82-TBX2*               rs2240736     17       61,408,032     T              MAP          0.35                                  0.35                     Kato et al. \[[@B20]\]
  *C20orf187*                   rs1887320     20       10,985,350     A              SBP          0.78                                  0.53                     Lu et al. \[[@B51]\]
  *C2orf43*                     rs2289081     2        20,682,080     C              PP           −0.223                                0.31                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *C5orf56*                     rs2188962     5        132,435,113    T              DBP          −0.2                                  0.14                     Liu et al. \[[@B23]\], Surendran et al. \[[@B29]\]
  *CACNA1D*                     rs9810888     3        53,601,568     G              DBP          0.39                                  0.39                     Lu et al. \[[@B51]\]
  *CACNA2D2*                    rs743757      3        50,438,947     C              DBP          0.245                                 0.36                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CACNB2*                      rs1813353     10       18,418,519     C              DBP          0.332                                 0.34                     Wain et al. \[[@B27]\]
  *CACNB2*                      rs11014166    10       18,419,869     A              DBP          0.46                                  0.21                     Levy et al. \[[@B9]\]
  *CAMKV-ACTBP13*               rs36022378    3        49,876,272     T              DBP          −0.202                                0.11                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CAPZA1*                      rs10745332    1        112,646,431    A              SBP          0.96                                  0.82                     Lu et al. \[[@B51]\]
  *CASC15*                      rs6911827     6        22,130,372     T              SBP          0.296                                 0.30                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CASZ1*                       rs880315      1        10,736,809     T              SBP          −0.475                                0.39                     Ehret et al. \[[@B12]\]
  *CCDC141*                     rs79146658    2        178,921,341    T              DBP          −0.311                                0.03                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CCDC41-CEP83-RN7SL483P*      rs139236208   12       94,486,966     A              PP           −0.363                                0.04                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CCNE1*                       rs62104477    19       29,804,084     T              DBP          0.177                                 0.19                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CD34*                        rs12731740    1        207,851,475    T              PP           −0.249                                0.08                     Warren et al. \[[@B26]\]
  *CDC42BPA*                    rs10916082    1        227,064,925    A              DBP          −0.177                                0.27                     Warren et al. \[[@B26]\]
  *CDH13*                       rs7500448     16       83,012,185     A              PP           0.329                                 0.17                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CDH17*                       rs2446849     8        94,091,269     T              SBP          −0.63                                 0.22                     Zhu et al. \[[@B32]\]
  *CELA2A*                      rs1042010     1        15,467,418     A              SBP          0.412                                 0.19                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CELA2A*                      rs3820068     1        15,471,702     A              SBP          0.425                                 0.19                     Wain et al. \[[@B27]\]
  *CEP164*                      rs8258        11       117,412,960    T              PP           0.236                                 0.47                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CEP68*                       rs74181299    2        65,056,838     T              PP           0.23                                  0.46                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CERS5*                       rs7302981     12       50,144,032     A              DBP          0.249                                 0.30                     Liu et al. \[[@B23]\], Surendran et al. \[[@B29]\]
  *CFDP1*                       rs11643209    16       75,297,146     T              SBP          −0.339                                0.47                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CHIC2*                       rs871606      4        53,933,078     T              PP           0.429                                 0.21                     Wain et al. \[[@B19]\]
  *chr15mb95*                   rs12906962    15       94,768,842     T              DBP          −0.221                                0.42                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *chr1mb25*                    rs6686889     1        24,703,979     T              DBP          0.185                                 0.37                     Warren et al. \[[@B26]\]
  *chr1mb9*                     rs9662255     1        9,381,890      A              PP           −0.207                                0.41                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CHST12-LFNG*                 rs2969070     7        2,472,910      A              DBP          −0.205                                0.21                     Ehret et al. \[[@B12]\]
  *CMIP*                        rs8059962     16       81,540,592     T              DBP          −0.170                                0.45                     Warren et al. \[[@B26]\]
  *CNNM2*                       rs11191548    10       103,086,421    C              SBP          1.082                                 0.09                     Wain et al. \[[@B27]\]
  *COL21A1*                     rs1925153     6        56,237,982     T              PP           −0.21                                 0.44                     Liu et al. \[[@B23]\]
  *CPEB4*                       rs72812846    5        173,950,633    A              DBP          −0.209                                0.11                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CRACR2B*                     rs7126805     11       828,916        A              PP           0.222                                 \<0.01                   Warren et al. \[[@B26]\]
  *CRK*                         rs12941318    17       1,430,304      T              SBP          −0.269                                0.37                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *CRYAA-SIK1-RRP1B*            rs12627651    21       43,340,723     A              SBP          0.503                                 0.19                     Ehret et al. \[[@B12]\], Surendran et al. \[[@B29]\]
  *CSK*                         rs1378942     15       74,785,026     A              DBP          0.371                                 0.65                     Wain et al. \[[@B27]\]
  *CYB561-LOC342541*            rs4459609     17       63,471,587     A              DBP          0.198                                 0.61                     Wain et al. \[[@B27]\]
  *CYP17A1-NT5C2*               rs1004467     10       102,834,750    A              SBP          1.2                                   0.16                     Levy et al. \[[@B9]\], Newton-Cheh et al. \[[@B10]\]
  *CYP1A1-ULK3*                 rs6495122     15       74,833,304     A              DBP          0.45                                  0.29                     Levy et al. \[[@B9]\], Newton-Cheh et al. \[[@B10]\]
  *CYP2C19*                     rs4494250     10       94,804,000     A              DPB          0.21                                  0.22                     Liu et al. \[[@B23]\]
  *DBH*                         rs6271        9        133,657,152    T              DBP          −0.423                                0.04                     Ehret et al. \[[@B12]\]
  *DNM3*                        rs12405515    1        172,388,301    T              DBP          −0.165                                0.47                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *DPEP1*                       rs1126464     16       89,637,957     C              DBP          0.275                                 0.26                     Liu et al. \[[@B23]\], Surendran et al. \[[@B29]\]
  *EBF1*                        rs11953630    5        158,418,394    T              DBP          −0.281                                0.18                     Johnson et al. \[[@B30]\]
  *EBF2*                        rs6557876     8        26,043,159     T              SBP          −0.411                                0.33                     Wain et al. \[[@B27]\]
  *ENPEP*                       rs6825911     4        110,460,482    C              DBP          0.39                                  0.42                     Kato et al. \[[@B22]\]
  *ESR1*                        rs13192976    6        151,991,280    A              PP           −0.332                                0.21                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FAF1*                        rs147696085   1        50,556,195     G              PP           0.298                                 0.06                     Hoffmann et al. \[[@B8]\]
  *FAM186B*                     rs7977389     12       49,587,939     T              PP           0.237                                 0.18                     Hoffmann et al. \[[@B8]\]
  *FAM208A*                     rs9827472     3        56,692,618     T              DBP          −0.177                                0.46                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FBLN5*                       rs2244643     14       91,892,678     A              PP           −0.213                                0.29                     Hoffmann et al. \[[@B8]\]
  *FBN2*                        rs6595838     5        128,532,506    A              SBP          0.344                                 0.41                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FBXL19*                      rs72799341    16       30,925,422     A              DBP          0.185                                 0.27                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FER1L5*                      rs7599598     2        96,686,103     A              DBP          −0.31                                 0.42                     Ganesh et al. \[[@B34]\]
  *FERMT2*                      rs9888615     14       52,910,822     T              SBP          −0.318                                0.36                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FGD5*                        rs11128722    3        14,916,619     A              SBP          −0.383                                0.41                     Ehret et al. \[[@B12]\]
  *FGF5*                        rs16998073    4        80,263,187     T              DBP          0.21                                  0.23                     Newton-Cheh et al. \[[@B10]\]
  *FGGY-HSD52*                  rs3889199     1        59,188,070     A              PP           0.351                                 0.14                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FIGN-PRPS1P1*                rs16849211    2        164,043,173    T              PP           0.364                                 0.23                     Wain et al. \[[@B27]\]
  *FIGN-PRPS1P1*                rs1446468     2        164,106,976    C              SBP          0.538                                 0.55                     Wain et al. \[[@B27]\]
  *FIGN-GRB14*                  rs16849225    2        164,050,310    C              SBP          0.75                                  0.23                     Ehret et al. \[[@B18]\], Kato et al. \[[@B22]\], Wain et al. \[[@B19]\]
  *FLJ32810-TMEM133*            rs633185      11       100,722,807    G              SBP          −0.565                                0.36                     Johnson et al. \[[@B30]\]
  *FN1*                         rs1250259     2        215,435,759    A              PP           −0.314                                0.23                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FNDC1*                       rs449789      6        159,278,093    C              PP           0.359                                 0.15                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *FOSL2*                       rs7562        2        28,412,873     T              SBP          0.263                                 0.50                     Warren et al. \[[@B26]\]
  *FRMD3*                       rs115795127   9        83,378,986     T              BP           NA                                    NR                       Liang et al. \[[@B35]\]
  *FURIN-FES*                   rs2521501     15       90,894,158     T              SBP          0.65                                  0.21                     Johnson et al. \[[@B30]\]
  *GATA2*                       rs62270945    3        128,483,046    T              PP           0.607                                 0.01                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *GJA1*                        rs11154027    6        121,460,244    T              PP           0.207                                 0.38                     Warren et al. \[[@B26]\]
  *GNAS-EDN3*                   rs6015450     20       59,176,062     G              SBP          0.896                                 0.10                     Johnson et al. \[[@B30]\]
  *GOSR2*                       rs17608766    17       46,935,905     T              SBP          −0.556                                0.05                     Johnson et al. \[[@B30]\]
  *GPAT2-FAHD2CP*               rs2579519     2        96,009,418     T              DBP          −0.197                                0.41                     Warren et al. \[[@B26]\]
  *GPATCH2*                     rs12408022    1        217,545,447    T              DBP          0.198                                 0.26                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *GPR20*                       rs34591516    8        141,356,987    T              SBP          0.323                                 0.05                     Surendran et al. \[[@B29]\]
  *GPR20*                       rs78192203    8        141,364,973    T              BP           NA                                    NR                       Liang et al. \[[@B35]\]
  *GPR98/ARRDC3*                rs10474346    5        91,268,322     C              DBP          1.1                                   0.31                     Fox et al. \[[@B36]\]
  *GTF2B*                       rs10922502    1        88,894,475     A              SBP          −0.382                                0.34                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *GUCY1A3*                     rs13143871    4        155,698,052    T              SBP          0.96                                  0.80                     Lu et al. \[[@B51]\]
  *GUCY1A3-GUCY1B3*             rs13139571    4        155,724,361    C              DBP          0.26                                  0.21                     Johnson et al. \[[@B30]\]
  *GYPA_HHIP*                   rs4292285     4        144,350,802    T              DBP          0.177                                 0.41                     Hoffmann et al. \[[@B8]\]
  *HAAO-RNU6-242P-AC016735.1*   rs13403122    2        42,851,618     C              DBP          0.226                                 0.20                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *HDAC9*                       rs2107595     7        19,009,765     A              PP           0.31                                  0.25                     Kato et al. \[[@B20]\]
  *HFE*                         rs1799945     6        26,090,951     G              DBP          0.457                                 0.09                     Johnson et al. \[[@B30]\]
  *HFE*                         rs1800562     6        26,092,913     A              DBP          0.394                                 0.06                     Wain et al. \[[@B27]\]
  *HIPK2*                       rs1011018     7        139,763,465    A              SBP          −0.329                                0.35                     Warren et al. \[[@B26]\]
  *HIVEP3*                      rs7515635     1        41,942,399     T              SBP          0.336                                 0.47                     Ehret et al. \[[@B12]\]
  *HM13-ID1*                    rs6060114     20       31,581,870     T              DBP          0.267                                 0.27                     Hoffmann et al. \[[@B8]\]
  *HNF4G-RNU2-54P*              rs1449544     8        75,679,645     A              PP           0.183                                 0.41                     Hoffmann et al. \[[@B8]\]
  *HOTTIP*                      rs1859168     7        27,202,740     C              DBP          0.436                                 0.92                     Wain et al. \[[@B27]\]
  *HOXA3*                       rs6969780     7        27,119,517     C              BP           NA                                    NR                       Liang et al. \[[@B35]\]
  *HOXA-EVX1*                   rs17428471    7        27,298,248     T              SBP          1.2                                   0.08                     Franceschini et al. \[[@B24]\]
  *HOXB7*                       rs7406910     17       48,610,894     T              SBP          −0.456                                0.12                     Surendran et al. \[[@B29]\]
  *HRCT1*                       rs76452347    9        35,906,474     T              DBP          −0.25                                 0.15                     Liu et al. \[[@B23]\]
  *HSD52-LOC105378756*          rs10889130    1        59,148,708     A              PP           0.288                                 0.33                     Wain et al. \[[@B27]\]
  *HSPB7*                       rs1048238     1        16,015,154     T              SBP          0.366                                 0.02                     Wain et al. \[[@B27]\]
  *IGFBP3*                      rs11977526    7        45,968,511     A              DBP          0.3                                   0.44                     Zhu et al. \[[@B32]\], Liu et al. \[[@B23]\]
  *INPP5B*                      rs871524      1        37,945,773     A              PP           0.228                                 0.33                     Wain et al. \[[@B27]\]
  *INSR*                        rs7248104     19       7,224,420      A              PP           −0.20                                 0.35                     Liu et al. \[[@B23]\]
  *INSR*                        rs36047283    19       7,255,690      G              SBP          0.801                                 0.11                     Wain et al. \[[@B27]\]
  *ITGA11*                      rs1563894     15       68,343,437     A              SBP          −0.093                                0.18                     Parmar et al. \[[@B37]\]
  *JAG1*                        rs1327235     20       10,988,382     G              DBP          0.302                                 0.46                     Johnson et al. \[[@B30]\]
  *JAG1-LOC101929395*           rs6040076     20       10,678,234     C              PP           0.285                                 0.49                     Wain et al. \[[@B27]\]
  *KCNH4-HSD17B1*               rs79089478    17       42,165,223     T              PP           0.584                                 0.01                     Warren et al. \[[@B26]\]
  *KCNK3*                       rs1275988     2        26,691,496     T              SBP          −0.6                                  0.41                     Ganesh et al. \[[@B34]\]
  *KIAA0753*                    rs7226020     17       6,570,508      T              PP           −0.256                                0.38                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *KIAA1462*                    rs9337951     10       30,028,144     A              PP           0.28                                  0.26                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *L3MBTL4*                     rs403814      18       6,282,594      A              BP           1.15                                  NR                       Liu et al. \[[@B23]\]
  *LHFPL2*                      rs10057188    5        78,541,966     A              PP           −0.205                                0.24                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *LINC01615-THBS2*             rs1322639     6        169,187,008    A              PP           0.316                                 0.33                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *LMO1*                        rs110419      11       8,231,306      A              DBP          0.159                                 0.43                     Surendran et al. \[[@B29]\]
  *LOC101928278*                rs10932679    2        216,787,868    T              PP           0.226                                 0.19                     Wain et al. \[[@B27]\]
  *LOC102723446*                rs10260816    7        45,970,501     G              PP           0.298                                 0.43                     Wain et al. \[[@B27]\]
  *LOC105369687-LOC105369688*   rs73075659    12       20,220,607     G              SBP          0.357                                 0.31                     Wain et al. \[[@B27]\]
  *LOC105370003*                rs11067763    12       115,760,536    A              DBP          0.51                                  0.62                     Lu et al. \[[@B51]\]
  *LOC105371811-LOC105371812*   rs79917357    17       48,747,312     A              SBP          0.342                                 0.17                     Wain et al. \[[@B27]\]
  *LOC105374567-LOC102723854*   rs72876037    2        42,967,456     T              SBP          0.534                                 0.12                     Wain et al. \[[@B27]\]
  *LOC105379231*                rs9693857     8        9,409,607      T              SBP          0.337                                 0.45                     Wain et al. \[[@B27]\]
  *LOC107986913-LOC105379224*   rs7826238     8        8,529,585      T              SBP          0.335                                 0.47                     Wain et al. \[[@B27]\]
  *LOC283335*                   rs73099903    12       53,046,995     T              SBP          0.768                                 0.06                     Wain et al. \[[@B27]\]
  *LRP12/ZFPM2*                 rs35783704    8        104,954,030    A              SBP          −0.609                                0.03                     Wain et al. \[[@B27]\]
  *LRRC10B-SYT7*                rs751984      11       61,510,774     T              MAP          0.33                                  0.27                     Kato et al. \[[@B20]\], Ehret et al. \[[@B12]\]
  *LSP1-TNNT3*                  rs661348      11       1,884,062      T              MAP          −0.65                                 0.42                     Johnson et al. \[[@B30]\]
  *MAP4*                        rs319690      3        47,885,994     T              DBP          0.282                                 0.41                     Wain et al. \[[@B19]\]
  *MAPK4-MRO*                   rs36010659    18       50,757,579     T              PP           0.25                                  0.12                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *MCF2L*                       rs9549328     13       112,981,842    T              SBP          0.318                                 0.22                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *MECOM*                       rs419076      3        169,383,098    T              SBP          0.409                                 0.42                     Johnson et al. \[[@B30]\]
  *METTL21A-AC079767.3*         rs55780018    2        207,661,416    T              SBP          −0.391                                0.35                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *MIR1263*                     rs16833934    3        164,019,462    G              DBP          −1.63                                 0.31                     Simino et al. \[[@B38]\]
  *MKLN1*                       rs13238550    7        131,374,297    A              SBP          0.331                                 0.33                     Warren et al. \[[@B26]\]
  *MOV10*                       rs12129649    1        112,688,881    T              DBP          0.548                                 0.06                     Wain et al. \[[@B27]\]
  *MRAS*                        rs2306374     3        138,401,110    T              DBP          −0.184                                0.08                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *MRC2*                        rs740698      17       62,689,790     T              PP           −0.228                                0.41                     Warren et al. \[[@B26]\]
  *MSRA*                        rs11249992    8        10,362,902     A              SBP          0.293                                 0.38                     Wain et al. \[[@B27]\]
  *MTAP*                        rs4364717     9        21,801,531     A              DBP          −0.175                                0.43                     Warren et al. \[[@B26]\]
  *MTF1-SF3A3*                  rs4360494     1        37,990,219     C              PP           0.278                                 0.38                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *MTHFR*                       rs17367504    1        11,802,721     G              DBP          0.526                                 0.15                     Wain et al. \[[@B27]\]
  *MTHFR-NPPB*                  rs4846049     1        11,790,308     T              DBP          −0.55                                 0.37                     Johnson et al. \[[@B30]\]
  *MYEOV*                       rs67330701    11       69,312,240     T              DBP          −0.367                                0.12                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *MYH6*                        rs452036      14       23,396,676     A              PP           −0.282                                0.34                     Liu et al. \[[@B23]\], Surendran et al. \[[@B29]\]
  *NADK-CPSF3L*                 rs139385870   1        1,754,504      D              SBP          −0.352                                0.33                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *NFKBIA*                      rs8904        14       35,402,011     A              SBP          0.377                                 0.40                     Wain et al. \[[@B27]\]
  *NME7*                        rs7519279     1        169,238,123    G              PP           0.218                                 0.13                     Hoffmann et al. \[[@B8]\]
  *NOS3*                        rs3918226     7        150,993,088    T              DBP          0.83                                  0.03                     Johnson et al. \[[@B30]\]
  *NOTCH3*                      rs10418305    19       15,167,997     C              PP           −0.282                                0.13                     Hoffmann et al. \[[@B8]\]
  *NOV*                         rs2071518     8        119,423,572    T              PP           0.312                                 0.32                     Wain et al. \[[@B19]\]
  *NOX4*                        rs2289125     11       89,491,285     A              PP           −0.377                                0.32                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *NPNT*                        rs13112725    4        105,990,585    C              SBP          0.435                                 0.34                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *NPPA-AS1, NPPA*              rs12744757    1        11,846,764     T              SBP          0.695                                 0.06                     Wain et al. \[[@B27]\]
  *NPR1*                        rs35479618    1        153,689,947    A              SBP          1.34                                  0.01                     Liu et al. \[[@B23]\]
  *NPR3-C5orf23*                rs1173771     5        32,814,922     C              SBP          0.63                                  0.34                     Johnson et al. \[[@B30]\], Kato et al. \[[@B22]\]
  *OBFC1*                       rs4387287     10       103,918,139    A              SBP          0.338                                 0.32                     Surendran et al. \[[@B29]\]
  *OR5B12*                      rs11229457    11       58,439,730     T              SBP          −0.312                                0.22                     Surendran et al. \[[@B29]\]
  *OSR1*                        rs1344653     2        19,531,084     A              PP           −0.27                                 0.38                     Kato et al. \[[@B20]\]
  *PABPC4*                      rs4660293     1        39,562,508     G              DBP          0.27                                  0.10                     Liu et al. \[[@B23]\]
  *PALLD-chr4mb174*             rs1566497     4        168,795,997    A              PP           0.236                                 0.23                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PAPPA2*                      rs61823001    1        176,664,440    G              PP           0.31                                  0.03                     Hoffmann et al. \[[@B8]\]
  *PAX2*                        rs112184198   10       100,844,757    A              SBP          −0.659                                0.05                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PDE10A*                      rs147212971   6        165,764,963    T              DBP          −0.360                                0.13                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PDE3A*                       rs12579720    12       20,020,830     C              DBP          −0.32                                 0.46                     Kato et al. \[[@B20]\]
  *PDE5A*                       rs66887589    4        119,588,124    T              DBP          −0.215                                0.50                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PHACTR1*                     rs9349379     6        12,903,725     A              SBP          0.289                                 0.38                     Surendran et al. \[[@B29]\]
  *PHIP*                        rs10943605    6        78,945,760     A              DBP          0.18                                  0.49                     Liu et al. \[[@B23]\]
  *PIK3CG*                      rs17477177    7        106,771,412    T              PP           −0.418                                0.17                     Wain et al. \[[@B19]\]
  *PKHD1*                       rs13205180    6        51,967,696     T              DBP          0.168                                 0.34                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PKN2-AS1*                    rs61767086    1        88,600,899     G              PP           0.413                                 0.14                     Wain et al. \[[@B27]\]
  *PLCB1*                       rs6108168     20       8,645,624      A              DBP          −0.211                                0.38                     Warren et al. \[[@B26]\]
  *PLCD3*                       rs12946454    17       45,130,754     T              SBP          0.28                                  0.21                     Newton-Cheh et al. \[[@B10]\]
  *PLCE1*                       rs932764      10       94,136,183     G              SBP          0.484                                 0.43                     Johnson et al. \[[@B30]\]
  *PLCE1*                       rs932764      10       94,136,183     G              SBP          0.484                                 0.44                     Ehret et al. \[[@B18]\]
  *PLEKHA7*                     rs177542      11       16,901,107     A              DBP          0.243                                 0.50                     Wain et al. \[[@B27]\]
  *PLEKHA7-NUCB2*               rs381815      11       16,880,721     T              SBP          0.84                                  0.21                     Levy et al. \[[@B9]\]
  *PLEKHG1*                     rs17080102    6        150,683,634    C              DBP          −0.74                                 0.12                     Franceschini et al. \[[@B24]\]
  *PNPT1*                       rs1975487     2        55,581,918     A              DBP          −0.217                                0.32                     Ehret et al. \[[@B12]\]
  *POC5-SV2C*                   rs10078021    5        75,742,606     T              DBP          −0.164                                0.46                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PPL*                         rs12921187    16       4,893,018      T              DBP          −0.174                                0.41                     Hoffmann et al. \[[@B8]\],Warren et al. \[[@B26]\]
  *PPP2R5E*                     rs8016306     14       63,461,828     A              SBP          0.335                                 0.41                     Warren et al. \[[@B26]\]
  *PRDM11*                      rs11442819    11       45,186,590     I              PP           −0.279                                0.13                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PRDM16*                      rs2493292     1        3,412,095      T              SBP          0.42                                  0.13                     Liu et al. \[[@B23]\]
  *PRDM6-SUMO1P5*               rs337100      5        123,210,816    A              PP           0.277                                 0.40                     Wain et al. \[[@B27]\]
  *PRDM6-CSNK1G3*               rs13359291    5        123,140,763    A              SBP          0.53                                  0.28                     Kato et al. \[[@B20]\]
  *PRDM8-FGF5*                  rs1902859     4        80,236,549     C              SBP          1.34                                  0.41                     Lu et al. \[[@B51]\]
  *PRDM8-FGF5*                  rs1458038     4        80,243,569     T              DBP          0.403                                 0.30                     Wain et al. \[[@B27]\]
  *PREX1*                       rs6095241     20       48,692,260     A              DBP          −0.168                                0.46                     Surendran et al. \[[@B29]\]
  *PRKAG1*                      rs1126930     12       49,005,349     C              PP           0.5                                   0.02                     Surendran et al. \[[@B29]\]
  *PRKCE*                       rs11690961    2        46,136,197     A              PP           0.34                                  0.04                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PRKD3*                       rs13420463    2        37,290,423     A              SBP          0.356                                 0.49                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *PROCR*                       rs867186      20       35,176,751     A              DBP          0.265                                 0.11                     Surendran et al. \[[@B29]\]
  *PRRC2A-BAG6*                 rs151168737   6        31,638,615     A              DBP          0.249                                 0.46                     Wain et al. \[[@B27]\]
  *PSMD5*                       rs10760117    9        120,824,459    T              SBP          0.334                                 0.42                     Ehret et al. \[[@B12]\], Liu et al. \[[@B23]\]
  *PYY*                         rs62080325    17       43,983,263     A              PP           −0.186                                0.21                     Warren et al. \[[@B26]\]
  *RABGAP1*                     rs10818775    9        122,993,292    C              PP           0.254                                 0.30                     Hoffmann et al. \[[@B8]\]
  *RAPSN, PSMC3, SLC39A13*      rs7103648     11       47,440,232     A              DBP          −0.203                                0.33                     Ehret et al. \[[@B12]\]
  *RBM47*                       rs35529250    4        40,426,074     T              SBP          −1.537                                \<0.01                   Surendran et al. \[[@B29]\]
  *RCOR2*                       rs4980532     11       63,913,247     T              PP           0.301                                 0.56                     Wain et al. \[[@B27]\]
  *RGL3*                        rs167479      19       11,416,089     T              DBP          −0.33                                 0.49                     Liu et al. \[[@B23]\], Surendran et al. \[[@B29]\]
  *RNF207*                      rs709209      1        6,218,354      A              PP           0.199                                 0.36                     Surendran et al. \[[@B29]\]
  *RP11-273G15.2*               rs62524579    8        142,979,538    A              DBP          −0.175                                0.48                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *RP11-321F6.1*                rs7178615     15       66,576,734     A              DBP          −0.179                                0.36                     Warren et al. \[[@B26]\]
  *RP11-435J9.2-TLN2*           rs956006      15       62,516,340     C              PP           0.188                                 0.23                     Hoffmann et al. \[[@B8]\]
  *RP11-439C8.2*                rs143112823   3        154,990,178    A              DBP          −0.403                                0.06                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *RP11-61O1.1*                 rs9323988     14       98,121,293     T              PP           −0.212                                0.29                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *RP4-710M16.1-PPAP2B-PLPP3*   rs112557609   1        56,111,252     A              PP           0.227                                 0.22                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *RPL34P18-CDH17*              rs7006531     8        94,098,516     G              BP           NA                                    NR                       Liang et al. \[[@B35]\]
  *RPL35P4-LOC107986733*        rs10279895    7        27,288,591     G              DBP          0.7553                                NR                       Liang et al. \[[@B35]\]
  *RPL35P4-LOC107986733*        rs11563582    7        27,312,031     A              BP           NA                                    NR                       Liang et al. \[[@B35]\]
  *RPL6-PTPN11-ALDH2*           rs11066280    12       112,379,979    T              DBP          1.01                                  0.04                     Kato et al. \[[@B22]\]
  *RPS29P9-LOC102724714*        rs3845811     2        207,656,788    G              SBP          0.284                                 0.43                     Wain et al. \[[@B27]\]
  *RRAS*                        rs61760904    19       49,636,675     T              SBP          1.499                                 \<0.01                   Surendran et al. \[[@B29]\]
  *RSPO3*                       rs13209747    6        126,794,309    T              DBP          0.56                                  0.35                     Franceschini et al. \[[@B24]\]
  *RYK*                         rs9859176     3        134,281,183    T              SBP          0.322                                 0.25                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SBNO1*                       rs1060105     12       123,321,672    T              DBP          −0.182                                0.18                     Surendran et al. \[[@B29]\]
  *SCAI-PPP6C*                  rs72765298    9        125,138,717    T              PP           −0.374                                0.06                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SDCCAG8*                     rs953492      1        243,307,890    A              DBP          0.22                                  0.49                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SENP2*                       rs12374077    3        185,599,886    C              DBP          0.163                                 0.42                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SEPT9*                       rs57927100    17       77,321,218     G              SBP          −0.489                                0.01                     Wain et al. \[[@B27]\]
  *SETBP1*                      rs12958173    18       44,562,012     A              SBP          0.386                                 0.25                     Ehret et al. \[[@B12]\]
  *SH2B3*                       rs3184504     12       111,446,804    T              SBP          0.75                                  0.33                     Levy et al. \[[@B9]\], Newton-Cheh et al. \[[@B10]\]
  *SLC12A9*                     rs7801190     7        100,860,471    C              BP           1.31                                  0.72                     Lettre et al. \[[@B39]\]
  *SLC14A2*                     rs7236548     18       45,517,785     A              PP           0.352                                 0.3                      Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SLC20A2*                     rs2978456     8        42,467,247     T              PP           −0.188                                0.45                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SLC24A3*                     rs6081613     20       19,485,263     A              PP           0.263                                 0.31                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SLC35F1*                     rs9372498     6        118,251,323    A              DBP          0.334                                 0.07                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SLC39A8*                     rs13107325    4        102,267,552    T              DBP          −0.684                                0                        Johnson et al. \[[@B30]\]
  *SLC4A7*                      rs11716531    3        27,415,717     A              DBP          0.213                                 0.237                    Wain et al. \[[@B27]\]
  *SLC4A7*                      rs13082711    3        27,496,418     T              DBP          −0.238                                0.12                     Johnson et al. \[[@B30]\]
  *SLC8A1*                      rs4952611     2        40,340,603     T              DBP          −0.157                                0.34                     Warren et al. \[[@B26]\]
  *SMARCA2-VLDLR*               rs872256      9        2,496,480      T              SBP          0.096                                 0.43                     Parmar et al. \[[@B37]\]
  *SNORD32B*                    rs926552      6        29,580,312     T              DBP          −0.31                                 0.07                     Liu et al. \[[@B23]\]
  *SNX31*                       rs2978098     8        100,664,447    A              DBP          0.165                                 0.34                     Warren et al. \[[@B26]\]
  *SOX6*                        rs4757391     11       16,281,393     C              DBP          0.49                                  0.28                     Lu et al. \[[@B51]\]
  *SSPN*                        rs6487543     12       26,285,256     A              SBP          0.3                                   0.46                     Warren et al. \[[@B26]\]
  *ST7L-CAPZA1-MOV10*           rs2932538     1        112,673,921    G              DBP          0.24                                  0.17                     Johnson et al. \[[@B30]\]
  *STK39*                       rs6749447     2        168,184,876    G              SBP          3                                     0.48                     Wang et al. \[[@B40]\]
  *SUGCT*                       rs76206723    7        40,408,372     A              PP           −0.346                                0.18                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *SULT1C3*                     rs6722745     2        108,258,788    C              SBP          0.28                                  0.4                      Liu et al. \[[@B23]\]
  *SVEP1*                       rs111245230   9        110,407,495    C              SBP          0.94                                  0.03                     Liu et al. \[[@B23]\]
  *SWAP70*                      rs2649044     11       9,742,422      T              DBP          0.2                                   0.547                    Wain et al. \[[@B27]\]
  *TBC1D1-FLJ13197*             rs2291435     4        38,385,774     T              SBP          −0.378                                0.4                      Ehret et al. \[[@B12]\]
  *TBX5-TBX3*                   rs2384550     12       114,914,926    A              DBP          −0.35                                 0.29                     Levy et al. \[[@B9]\], Kato et al. \[[@B22]\]
  *TCF7L1*                      rs11689667    2        85,264,242     T              PP           0.176                                 0.28                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *TCF7L2*                      rs34872471    10       112,994,312    T              PP           −0.226                                0.24                     Hoffmann et al. \[[@B8]\]
  *TEX41*                       rs1438896     2        144,888,505    T              DBP          0.234                                 0.3                      Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *TEX41*                       rs55944332    2        144,969,054    G              DBP          0.267                                 0.24                     Wain et al. \[[@B27]\]
  *TFAP2D*                      rs78648104    6        50,715,296     T              SBP          −0.481                                0.09                     Warren et al. \[[@B26]\]
  *TM6SF1*                      rs2034618     15       83,130,880     C              DBP          0.21                                  0.22                     Hoffmann et al. \[[@B8]\]
  *TMEM161B*                    rs10059921    5        88,218,698     T              SBP          −0.526                                0.06                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *TMEM194B-NEMP2-NAB1*         rs7592578     2        190,574,865    T              DBP          −0.240                                0.18                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *TNRC6A*                      rs11639856    16       24,777,324     A              SBP          −0.37                                 0.17                     Liu et al. \[[@B23]\]
  *TNRC6B*                      rs470113      22       40,333,610     A              PP           −0.253                                0.21                     Surendran et al. \[[@B29]\]
  *TNS1*                        rs1063281     2        217,804,009    T              DBP          −0.200                                0.43                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *TNXB*                        rs2021783     6        32,077,074     C              DBP          0.49                                  0.79                     Lu et al. \[[@B51]\]
  *TNXB*                        rs185819      6        32,082,290     C              SBP          0.365                                 0.513                    Wain et al. \[[@B27]\]
  *TP53-SLC2A4*                 rs78378222    17       7,668,434      T              PP           0.904                                 0                        Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *TRAPPC9*                     rs4288356     8        140,045,627    A              PP           0.224                                 0.615                    Wain et al. \[[@B27]\]
  *TRAPPC9*                     rs4454254     8        140,049,929    A              PP           −0.261                                0.45                     Warren et al. \[[@B26]\]
  *TRIM36*                      rs10077885    5        115,054,424    A              DBP          −0.194                                0.42                     Ehret et al. \[[@B12]\]
  *UBA52P4-LOC105377005*        rs820430      3        27,507,409     A              SBP          0.76                                  0.32                     Lu et al. \[[@B51]\]
  *ULK4*                        rs7651190     3        41,724,463     G              BP           NA                                    NR                       Liang et al. \[[@B35]\]
  *ULK4*                        rs9815354     3        41,912,651     A              DBP          0.6                                   0.17                     Levy et al. \[[@B9]\]
  *ULK4*                        rs7372217     3        41,948,630     G              BP           NA                                    NR                       Liang et al. \[[@B35]\]
  *UMOD*                        rs13333226    16       20,354,332     NA             HTN          NA                                    0.24                     Padmanabhan et al. \[[@B25]\]
  *VAC14*                       rs117006983   16       70,721,707     A              PP           0.986                                 0                        Warren et al. \[[@B26]\]
  *WNT3A*                       rs2760061     1        228,003,374    A              DBP          0.23                                  0.35                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *XKR6*                        rs10107145    8        10,900,703     G              SBP          0.361                                 0.528                    Wain et al. \[[@B27]\]
  *XRCC6*                       rs73161324    22       41,642,782     T              PP           0.496                                 0.02                     Warren et al. \[[@B26]\]
  *ZBTB38*                      rs16851397    3        141,415,976    A              DBP          −0.493                                0.05                     Surendran et al. \[[@B29]\]
  *ZC3HC1*                      rs11556924    7        130,023,656    T              DBP          −0.214                                0.27                     Ehret et al. \[[@B12]\]
  *ZFAT*                        rs894344      8        134,600,502    A              SBP          −0.258                                0.47                     Warren et al. \[[@B26]\]
  *ZNF101*                      rs2304130     19       19,678,719     A              DBP          −0.292                                0.11                     Surendran et al. \[[@B29]\]
  *ZNF318-ABCC10*               rs10948071    6        43,312,975     T              PP           −0.38                                 0.43                     Ganesh et al. \[[@B34]\]
  *ZNF385B*                     rs13407401    2        179,850,979    A              SBP          0.434                                 0.291                    Wain et al. \[[@B27]\]
  *ZNF638*                      rs3771371     2        71,400,409     T              PP           −0.160                                0.37                     Hoffmann et al. \[[@B8]\], Warren et al. \[[@B26]\]
  *ZNF652*                      rs12940887    17       49,325,445     T              DBP          0.26                                  0.374                    Wain et al. \[[@B27]\]
  *ZNF652*                      rs16948048    17       49,363,104     G              DBP          0.39                                  0.29                     Newton-Cheh et al. \[[@B10]\]
  *ZNRF3*                       rs4823006     22       29,055,683     G              SBP          −0.33                                 0.45                     Liu et al. \[[@B23]\]

SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; MAP: mean arterial pressure; HTN: hypertension; NR: not recorded; NA: not available.

[^1]: Academic Editor: Raffaele Pezzani
